ResMed | RMD - Cash And Equivalent


ResMed reported $1.47B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Ansell USD 238.3M 674M Jun/2025
Artivion USD 77.32M 21.55M Jun/2026
AtriCure USD 167.79M 21.62M Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Cochlear AUD 275.7M 107.4M Jun/2025
Cooper Companies USD 138.8M 13.9M Mar/2026
CSL USD 2.16B 633M Jun/2025
Dexcom USD 1.1B 13.2M Jun/2026
Edwards Lifesciences USD 2.9B 500M Jun/2026
Fisher Paykel Healthcare NZD 461.1M 371.2M Jun/2026
Globus Medical USD 507.74M 53.2M Jun/2026
Haemonetics USD 223.38M 22.06M Jun/2026
Idexx Laboratories USD 196.93M 3.6M Jun/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 534.9M 54.5M Jun/2026
Integra LifeSciences USD 214.42M 22.39M Jun/2026
Intuitive Surgical USD 8.63B 646.3M Jun/2026
Medtronic USD 1.69B 258M Jun/2026
Philips EUR 1.79B 803M Jun/2026
Ramsay Health Care AUD 784.4M 443.3M Jun/2025
ResMed USD 1.47B 191.28M Jun/2026
Sigma Healthcare AUD 16.65M 3.68M Jan/2023
Sonic Healthcare AUD 645M 25.39M Jun/2024
Steris USD 482.3M 42.7M Jun/2026
Teleflex USD 300.16M 9.25M Jun/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026